Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 524 of 5804
-
New hope for lung cancer patients with brain tumors: targeted drug T-DXd enters trial
Disease control ENROLLING_BY_INVITATION'1. Objective * Primary objective \- Median Intracranial Progression-free survival(icPFS) as defined by RANO(Response Assessment in Neuro-Oncology) criteria * Secondary objective * Progression free survival(PFS) as defined by RECIST 1.1 * Median Intracranial progression …
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Mpox drug TPOXX put to the test in 328-Patient trial
Disease control CompletedThe purpose of the PALM007 extension is to further characterize the clinical and natural history of mpox, and to provide standard of care (SOC) during the ongoing outbreaks.
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 14:10 UTC
-
New hope for kids with tough cancers: precision drugs tested
Disease control Recruiting nowA companion platform trial to test novel targeted agents based on the patient's tumor profile.
Phase: PHASE1, PHASE2 • Sponsor: Australian & New Zealand Children's Haematology/Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for rare cancers: daratumumab trial targets Hard-to-Treat lymphomas
Disease control Recruiting nowBackground: Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are aggressive forms of cancer that affects cells in the immune system and lymph nodes. How they develop is not well understood, and these diseases do not respond …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a lab test on your own tumor cells beat glioblastoma?
Knowledge-focused Recruiting nowPatient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.
Phase: NA • Sponsor: Medical University of Vienna • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control Recruiting nowThis phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable). Durvalumab is a monoclonal antibody …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Heart attack survivors: could a new shot clear your clogged arteries?
Disease control Recruiting nowThis study is to evaluate the effect of Inclisiran on coronary atherosclerosis using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in patients with acute myocardial infarction and elevated low-density lipoprotein cholesterol (LDL-C).
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Blood DNA fragments and MRI join forces to spot hidden prostate cancer
Diagnosis TerminatedThe goal of this diagnostic test is to obtain multiple cell-free DNA (cfDNA) fragment profiles of subjects by whole genome sequencing based on plasma cfDNA, build a prostate cancer prediction model by machine learning, and to validate the efficacy of this model in patients who ne…
Sponsor: Shanghai Changzheng Hospital • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New hope for rare bone cancer: targeted pill slows tumor growth?
Disease control Recruiting nowStudy CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mu…
Phase: PHASE3 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug aims to normalize liver enzyme in bile duct disease
Disease control CompletedThe participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease. Primary biliary cholangitis is a slowly progressive disease cha…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for MOGAD patients: drug aims to stop relapses
Disease control OngoingThe purpose of the study is to evaluate the safety and efficacy of Tocilizumab in MOGAD.
Phase: PHASE2, PHASE3 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human trials
Disease control Recruiting nowThis is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a simple infusion stop Immunotherapy's worst side effects?
Disease control Recruiting nowThis phase II trial studies how well giving siltuximab during the reintroduction (rechallenge) of immune checkpoint inhibitor (ICI) therapy works in preventing severe immune-related adverse events (irAEs) in patients with cancer that may have spread from where it first started to…
Phase: PHASE2 • Sponsor: Yuanquan Yang • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New antibody drug aims to unleash immune system on Hard-to-Treat cancers
Disease control Recruiting nowThis clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels …
Phase: PHASE1, PHASE2 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New cocktail of drugs shows promise for rare, aggressive tumors
Disease control OngoingThis is an open label, single arm, phase II multicentre study designed to evaluate the efficacy and safety of pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy in patients with HG-NETs who are che…
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for veterans: therapy combo targets PTSD and suicide risk
Disease control Recruiting nowPosttraumatic Stress Disorder (PTSD) is a significant driver of suicide risk among Veterans, but there is a critical knowledge gap about how to treat PTSD among people at elevated risk for suicide. Although evidence-based treatments for PTSD reduce suicide risk, Veterans at high …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Brain pacemaker offers hope for severe OCD
Disease control Recruiting nowThere are two primary approaches to the treatment of OCD, pharmacotherapy and cognitive behavior therapy (CBT). Lack of therapeutic success with one approach leads to trials of the alternative approach or a combination of the two. A rarely used third therapy approach, appropriate…
Phase: NA • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for tough leukemia: Three-Drug combo trial launches
Disease control Recruiting nowThe purpose of this prospective, multi-center, single-arm, phase 2 study is to evaluate the efficacy and safety of a combination regimen of mitoxantrone hydrochloride liposome injection, standard-dose of cytarabine and venetoclax (MAV) in the treatment of relapsed or refractory (…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 26, 2026 17:42 UTC
-
Can a new drug help PAH patients breathe easier during exercise?
Disease control CompletedThe purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New shot shows promise for tough eczema in phase 3 trial
Disease control CompletedThis study will evaluate the efficacy and safety of SIM0718 in adolescents (12- \< 18 years) and adults (18-75 years) with moderate to severe AD.
Phase: PHASE3 • Sponsor: Simcere Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC